Personalis Receives New Order from the VA’s Million Veteran Program – Total Awarded to Date Now $145M
27 9월 2019 - 5:05AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced a new task order under its contract
with the U.S. Department of Veterans Affairs (VA) for the VA’s
Million Veteran Program (VA MVP). The new task order is effective
on September 28, 2019. This is the largest single task order
received to date and has a value of up to approximately $38.1M,
subject to the receipt of samples from the VA MVP and performance
of services by Personalis. The cumulative value of task orders
received to date from the VA MVP has increased to approximately
$145M.
Personalis was first contracted by the VA MVP to provide DNA
sequencing and data analysis services in 2012. Since then,
Personalis has invested in technology and infrastructure to expand
its high-volume capabilities and has developed sophisticated data
systems for sample tracking, processing, and for managing large
amounts of genetic data.
Personalis CEO, John West, said, “We are proud of our continuing
relationship with the VA MVP, which represents the largest portion
of our revenue. Given the current backlog of VA MVP samples
in-house and the additional samples we may receive under this new
task order, we expect that over the next several quarters our VA
MVP business will account for a higher proportion of our total
revenue than previously expected. Our experience delivering
cutting-edge solutions for biopharma customers has allowed us to
deliver a differentiated service to the VA MVP. Additionally, our
VA MVP business is well aligned with our oncology business:
efficient high-quality processing of tens of thousands of samples
is important to both and we expect cancer sequencing to move to
whole genome over time. Our work at the forefront of oncology has
allowed us to develop the technologies and skillsets that help us
support the VA MVP.”
About the VA Million Veteran Program
Launched in 2011, the VA MVP is a landmark research effort aimed
at better understanding how genetic variations affect health. Up to
a million veterans are expected to enroll in the VA study by 2021.
Data and genetic samples collected through the program are stored
securely and made available for studies by authorized researchers,
with stringent safeguards in place to protect Veterans’ private
health information. The VA MVP is now enrolling veterans at 63 VA
medical centers nationwide in the study. The VA’s central
biorepository is equipped with a state-of-the-art robotic system
for DNA extraction and storage and is currently being expanded to
support up to 4 million samples. With more than 775,000 enrollees
since 2011, the VA MVP already far exceeds the enrollment numbers
of any single VA study or research program in the past, and is in
fact one of the largest research cohorts of its kind in the
world.
The VA MVP provides researchers with a rich resource of genetic,
health, lifestyle, and military-exposure data collected from
questionnaires, medical records, and genetic analyses. By combining
this information into a single database, the VA MVP promises to
advance knowledge about the complex links between genes and
health.
Veterans’ privacy and confidentiality are top priorities in the
VA MVP, as in all VA research. For more information about the VA
MVP, visit www.research.va.gov/MVP. This press release does not
imply a Department of Veterans Affairs endorsement, and is neither
paid for nor sponsored, in whole or in part, by any element of the
United States government.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc)
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. For example,
forward-looking statements include statements regarding: the timing
and quantity of samples received from the VA MVP; the extent to
which Personalis realizes revenue, if any, from the VA MVP contract
and task orders thereunder; the enrollment of veterans in the VA
MVP study, and ongoing demand of the VA MVP for Personalis’
services; and developments in whole genome cancer sequencing. These
forward-looking statements are subject to risks and uncertainties,
including those discussed in Personalis’ filings with the
Securities and Exchange Commission, including in the “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” sections of the Company’s most recently
filed periodic reports on Form 10-Q and subsequent filings and in
the documents incorporated by reference therein. Except as
otherwise required by law, Personalis disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date hereof, whether as a result of new
information, future events or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190926005829/en/
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024